Metformin combined with anti-PD-1 led to a 6.4-fold increase in NK cells compared to the anti-PD1 single treatment group, while metformin single treatment led to a 3.9-fold increase in NK cells compared to the control group in B16F10 tumor-bearing mice. Here, PDCD1 is linked to neoplasm.